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Abstract
Background: Sarcoidosis is thought to be a T-helper type 1 cytokine (Th2 cytokine) mediated
disorder. Induced sputum (IS) has been proposed as a useful non-invasive method, mainly for the
assessment of the airway diseases. The aim of this study was to explore induced sputum (IS)
CD4+Th1 T-lymphocyte subpopulation and to compare them with those of bronchoalveolar lavage
fluid (BALF) in patients with sarcoidosis.
Methods: We studied prospectively 21 patients (12 female, 9 male) of median age 46 yr (range,
25–65) with sarcoidosis and 10 normal subjects (5 female, 5 male) of median age 39 yr (range, 26–
60). IS was performed with hypertonic saline solution using an ultrasonic nebulizer. BALF was
performed within 10 days of IS. After stimulation of sputum lymphocytes with phorbol-myristate-
acetate, we used double immunocytochemical methods to identify CD4+ IFN-γ  positive and IL-4
positive cells (Th1 and Th2, respectively).
Results: Sarcoidosis patients had an increased number of CD4+ -IFN-γ  producing cells in IS (p =
0.003) and BALF (p = 0.01) in comparison with normal subjects. No significant differences were
detected between CD4+ -IL-4 cells in BALF (p = 0.053, NS) and IS (p = 0.46, NS) between
sarcoidosis patients and healthy controls. The ratio of Th1 to Th2 cells in BALF and IS was
statistically different in sarcoidosis when compared with normal subjects (p = 0.007 in BALF and
IS). A significant correlation was found between CD4+ IFN-γ  positive cells in IS and those in BALF
in sarcoidosis patients (r = 0.685, p = 0.0006).
Conclusion: These data suggests that a Th1-like cytokine pattern can be observed in CD4+ T-
lymphocytes in IS in patients with pulmonary sarcoidosis. Further studies are needed to explore
the value of IS vs BALF in the follow-up of these patients.
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Background
Sarcoidosis is a chronic, systemic disease of unknown ori-
gin, characterized by the formation of noncaseating gran-
ulomas in affected organs, most commonly the lung.
According to the ATS/ERS/WASOG [1] statement on sar-
coidosis, the diagnosis is based on clinical and radiologi-
cal findings and on histologic evidence. The technical
availability of the fiberoptic bronchoscope has facilitated
the development of the bronchoalveolar lavage proce-
dure, which is useful for the collection of cells and secre-
tions from the lower respiratory tract. Although this
technique causes low risk to the patient, it is relatively
invasive and inconvenient for the patients. Sputum induc-
tion has been proposed as a non-invasive method, useful
to the investigation of asthma [3], and also of other inter-
stitial lung disease (ILD) [4,5], more specifically sarcoido-
sis [4,6-9], pneumoconiosis due to dust exposure [10],
Crohn's disease [11] and non-granulomatous ILD [4]. The
exact role of induced sputum in the diagnosis and evalua-
tion of disease activity in ILD and especially in sarcoidosis
has not been clearly defined. Furthermore, no specific
studies have been undertaken to evaluate the safety and
functional effects of induced sputum in patients with ILD
[5]. Today's attitude and opinion of researchers in this
area is that induced sputum is a promising technique in
assessing ILD, but its diagnostic role has not yet been clar-
ified, and should be used as a complimentary tool to BAL
for research and clinical monitoring [5,12].
The pathogenesis of pulmonary sarcoidosis has been
related to an increased production of Th1-like cytokines.
However cytokine expression in sarcoidosis has not been
systematically studied yet. It is well known that CD4+ T
cells can be divided in two subgroups on the basis of their
cytokines profile. Th1 cells produce type 1 cytokines {IL-
2, tumor necrosis factor-(TNF)-α , interferon gamma-
(IFN-γ )}, while Th2 cells produce type 2 cytokines (IL-4,
IL-5, IL-6, IL-10, IL13).
As far as we know there are only a few studies regarding
the Th1/Th2 balance in sarcoidosis and all of them either
in bronchoalveolar lavage fluid (BALF) or in blood [13-
15]. Therefore, the aim of this study was to explore
induced sputum (IS) CD4+ Th1 T-lymphocyte subpopula-
tion and to compare them with those in the BALF in
patients with sarcoidosis.
Methods
Subjects
The demographic and clinical characteristics of the
patients and controls are shown in Table 1. Twenty-one
consecutive sarcoidosis patients, 9 male and 12 female, of
median (range) age 46 (25–65) years who were investi-
gated in the sarcoidosis clinic of our Hospital were
enrolled in the study. Three of them were smokers and 18
non-smokers. The ATS/ERS/WASOG statement [1] on sar-
coidosis was followed for the diagnosis, based on history,
clinical symptoms, standard chest radiography, computed
tomography, lung Ga67 scintigraphy and laboratory tests
(serum angiotensin-converting enzyme). All of them had
transbronchial or open lung biopsy with histopathologi-
cal evidence of noncaseating epithelioid cell granulomas.
According to chest radiography classification of sarcoido-
sis, 8 had type I disease (lymphadenopathy alone, 7 type
II disease (lymphadenopathy and parenchymal opaci-
ties), and 6 type III disease (only parenchymal opacities).
The control group included 10 healthy nonsmoker volun-
teers (5 female, 5 male), median (range) age 39 (26 – 60)
years who were able to produce adequate sputum samples
following sputum induction. Patients and controls with
acute respiratory infection during the 6 weeks prior to the
study were excluded. The Ethics committee of our hospital
approved the protocol and all patients and controls gave
their consent.
Spirometry
Spirometry was performed with a computerized system
(MasterLab, Jaeger2.12, Germany). The measurement was
performed using standard protocols according to ATS
guidelines [16].
Sputum induction
Sputum was induced by the inhalation of hypertonic
saline aerosol solution, generated by an ultrasonic neb-
ulizer (Ultraneb 2000, DeVilbiss, Somerset, PA, USA), as
previously described [6,17,18].
Sputum processing
Sputum was processed within 1 hour after termination of
the induction. The method of sputum examination
Table 1: Demographic and spirometric characteristics of 
sarcoidosis patients and control subjects. Values are expressed 
as mean ± SD, and age as median (range).
Characteristics Sarcoidosis Normal subjects
Number 21 10
Sex: Male/Female 12/9 5/5
Age, yr 46 (25–65) 39 (26–60).
Smokers/non smokers 18/3 0/10
FVC, % pred 93.1 ± 6.4 103 ± 13.7
FEV1, % pred 92.3 ± 6.6 101.1 ± 19
FEV1 / FVC, % pred 95.3 ± 5.9 100.3 ± 8.6
K CO % pred 82.3 ± 8.1 96 ± 6.3
Radiographic Stage (n) I: 8, II: 7,III: 6
Abbreviations: KCO = Carbon monoxide transfer coefficient, FVC % 
pred : Forced vital capacity % predicted, FEV1 % pred : Forced 
expiratory volume within the first second % predictedBMC Pulmonary Medicine 2005, 5:8 http://www.biomedcentral.com/1471-2466/5/8
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described earlier [17,18] was used with some modifica-
tions [6].
Bronchoalveolar lavage
Fiberoptic bronchoscopy with BAL was performed within
two weeks from the IS, as part of routine clinical manage-
ment, according to recommended guidelines and previ-
ous reports [6,20].
BALF processing
The recovered BAL fluid was filtered through sterile gauze
(Thompson, Ontario, Canada) and centrifuged at 400 g
for 15 minutes at 4°C. Total cell counts were determined
using an improved Neubauer counting chamber, and
expressed as the total number of cells per mL of aspirated
fluid. The pellet was washed three times with cold PBS-
Dulbecco's and the cells were adjusted to a final concen-
tration of 106cells/mL with RPMI1640 plus 2%FCS. The
slide preparation was performed as previously reported
[6].
Immunocytochemical analysis
The immunocytochemical analysis and T-cell determina-
tion were performed in sputum cytospins. Briefly, sputum
lymphocytes were stimulated by incubating suspension B
in 24-well plates at a concentration of 2 × 103 cells/µL for
5 h, under 5% CO2, at 37°C, in RPMI-1640 at 10% FCS in
the presence of phorbol 12-myristate 13 acetate (PMA) 25
ng/mL, ionomycin 1 µmoL and Brefeldin A 10 µg/Ml
(Sigma-AldrichCorp. St.Louis, MO, USA). Cytospins were
made using cytocentrifugation of 50 µL of the stimulated
suspension and were stored at -80°C for immunocyto-
chemical analysis later. Approximately 175,000 cells were
cytospined on each slide (3500 cells/µl × 50 µl = 175,000
cells), among which there was a sufficient number of lym-
phocytes to stain.
After defrosting the slides, they were fixed in acetone for
10 min and rehydrated in Tris-Buffered Saline (TBS). The
double immunocytochemical method was performed in
two steps as previously described [21]. Briefly, the speci-
mens were first incubated for 30 min with bovine serum
to block the unspecific binding and then were exposed to
the first primary antibody at a dilution of 1:50 for 30 min
at room temperature. After washing inTBS three times
they were exposed to the first secondary antibody, rabbit
anti mouse immunoglobulin fluorescein isothiocyanate
(FITC)-conjugated for 15 min (ImmunotechMarseille,
France) at a dilution of 1:50. After washing in TBS three
times they were exposed to the secondary primary anti-
body at a dilution of 1:50 for 30 min at room tempera-
ture. After washing in TBS three times they were exposed
to the second secondary antibody, rabbit anti-mouse
immunoglobulin phycoerythrin-conjugated (IgG-PE) for
15 min (Immunotech Marseille, France) at a dilution of
1:50. After washing in TBS three times the slides were
mounted with 30% glycerol in TBS. Two investigators
examined the slides under ultraviolet microscope and
their results were averaged. Three replicate measurements
were performed by each observer in 10 slides. Both intra-
and inter- observer coefficient of variation were <15%.
The ratio of CD4+-IFN-γ  positive cells to CD4+-IL4 posi-
tive cells was calculated. For the estimation of each ratio,
500 T-cells were counted with more than one cytospin
stained if necessary, because this number was sufficient to
obtain a mean value per subject that remained constant
after further increasing the number of cells counted.
Results were also expressed as percentage of lymphocytes
by dividing the number of lymphocytes stained per slide
by total the number of lymphocytes per slide. Negative
controls were obtained by the use of mouse-anti-mouse
immunoglobulin to estimate the non specific binding.
Positive controls were obtained by the use of T-lymphoma
cells cytospined on slides. Macrophages were excluded
from counting by morphology.
Measurement of CD4+-IFN-γ  and CD4+-IL4 producing T-
cells
The primary anti CD4 mouse anti-human monoclonal
antibody with secondary rabbit anti-mouse IgG- FITC
antibody and the primary anti-IFN-γ  mouse antihuman
monoclonal antibody (Caltag Burlingame, CA, USA) with
secondary rabbit antimouse IgG-phycoerythrin-conju-
gated (IgG-PE) antibody were used. At least 500 CD4+
cells were counted to estimate the number of CD4+-IFN-γ
cells. Also the same method was applied for staining
CD4+-IL-4 producing cells with anti-IL4 antibody (Caltag
Burlingame, CA, USA).
Statistics
All analyses were performed using the statistical software
StatsDirect for Windows version2.4.1 (Camcode;
Cambridge, UK). Results are expressed as mean ± SD, or
median (range), unless otherwise indicated. The Shapiro-
Wilk W test for normality was applied to assess normality.
Differences between sarcoidosis patients and controls
were tested usingt-test for normally and the Mann-Whit-
ney U test for non normally distributed data. Differences
between the BALF and sputumwithingroupswere tested
using the paired student's t-test for normally and theWil-
coxon's signed rank test for non-normally distributed var-
iables. Correlation between cell numbers and T
lymphocyte subsets were analyzed using the Pearson's
correlation coefficient. A p value of <0.05 was considered
as statistically significant
Results
Patients with sarcoidosis were older than normal control
subjects and had lower FVC, and FEV1 values but the
differences were not statistically significant. Induced spu-BMC Pulmonary Medicine 2005, 5:8 http://www.biomedcentral.com/1471-2466/5/8
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tum and BALF were tolerated well by all subjects, without
any adverse events (Table 1).
In BALF the percentage of IFN-γ  producing CD4+ Tcells
was significantly higher in patients with sarcoidosis than
in normal control subjects (mean ± SD, 53.1 ± 17.9 versus
38.1 ± + 7.7, p = 0.019) after the stimulation with PMA/
ionomycin. In induced sputum the percentage of IFN-γ
producing CD4+ T cells was significantly higher in
patients with sarcoidosis than in normal control subjects
(mean ± SD, 60.0 ± 23.3 versus 35.60 ± 12.46, p = 0.003)
after the stimulation. No significant differences were
detected between sarcoidosis patients and control subjects
regarding the proportion of IL-4 producing CD4+ T cells
in BALF (p = 0.46) as well as in induced sputum (p =
0.055) (Table 2). The ratio Th1/Th2 was found signifi-
cantly higher in BALF (p = 0.007) and also in induced spu-
tum compared with healthy controls.
No statistically significant difference was found between
induced sputum and BALF within groups (paired t test). A
significant correlation was found between BALF and IS in
the percentage of IFN-γ  producing CD4+ T cells counts (r=
0. 685, p = 0.006) (Figure 1).
Discussion
To the best of our knowledge this is the first study in the
literature to investigate the balance Th1/Th2 in sarcoido-
sis with the method of induced sputum. The main finding
of this study is that a Th1-like cytokine pattern can be
observed in CD4+ BALF as well as induced sputum T lym-
phocytes. We also detected a positive correlation between
CD4+ IFN-γ  producing T cells in induced sputum and
those in BALF in sarcoidosis patients (p = 0.0006, r =
0.685).
We have previously shown that inflammation in sarcoido-
sis could be effectively and non-invasively determined by
the analysis of cell differential counts and T-lymphocyte
subsets in induced sputum [6]. We demonstrated that
induced sputum can discriminate between patients with
sarcoidosis and normal subsets on the basis of the profile
of airway inflammatory cells, including lymphocytes [6].
Based on our findings that there is a positive correlation
between BALF and induced sputum lymphocyte counts (r
= 0.616) and CD4+/CD8+ ratio (r = 0.7) we aimed to eval-
uate the Th1/Th2 balance in sarcoidosis in both BALF and
induced sputum. As it has already been reported, the
mean CD4+/CD8+ ratio was not significantly different
between BALF and induced sputum in 20 sarcoidosis
patients (p > 0.253) and in normal controls (p > 0.3). In
our study population a CD4+/CD8+ ratio ≥  2.5 was found
on 17 patients in induced sputum, while a CD4+/CD8+
ratio > 4 was found in 12 (60%) patients [6].
The balance between Th1 and Th2 helper cells and their
associated cytokine patterns can in an immune response
influence the phenotype and progression of several
clinical diseases. An imbalance in the expression of Th1
and Th2 type cytokines by alveolar cells is thought to play
an important role in the immunopathogenesis of sar-
Table 2: Mean ± SD of Th1, Th2 lymphocyte subsets in induced sputum (IS) and bronchoalveolar lavage fluid (BALF) in sarcoidosis 
patients and control subjects.
Induced sputum BALF
Th1 Th2 Th1 Th2
Control 35.6 ± 12.4 0.2 ± 0.15 38.1 ± 7.7 0.3 ± 0.14
Sarcoidosis patients 60.0 ± 23.3 0.2 ± 0.12 53.1 ± 17.9 0.2 ± 0.11
P 0.003 0.46 0.019 0.55
* Paired t-test or Wilcoxon's signed rank test, unadjusted p-values.
Correlation of CD4+ IFN-γ  cells between bronchoalveolar  lavage fluid (BALF) and induced sputum (IS) Figure 1
Correlation of CD4+ IFN-γ  cells between bronchoalveolar 
lavage fluid (BALF) and induced sputum (IS).BMC Pulmonary Medicine 2005, 5:8 http://www.biomedcentral.com/1471-2466/5/8
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coidosis [22-26]. Previous authors have shown a sponta-
neous release from alveolar cells of the Th1 type cytokines
IFN-γ  and IL-2 but not Th2 type cytokines [24,26-29].
Additionally, there are no data on cytokine profiles in the
late stages of fibrotic sarcoidosis to assess the contribution
of Th1 or Th2 cytokines to the fibrotic process. Experi-
mental models confirm that Th2-mediated granuloma-
tous responses are more fibrotic than Th1-mediated
inflammation, so in the absence of human data, there is
uncertainty as to the relevant immune processes in
fibrotic pulmonary sarcoidosis. Conceivably, patients
with fibrotic sarcoidosis are those who switch to a more
fibrotic Th2 response later in the course of the disease, or
have a persistent dominant Th2 response from the iniatial
stages of disease [29,30]. Furthermore, data support the
immunopathogenetic concept of compartmentalization
and the predominance of CD4+ T cells producing mainly
Th1 type cytokines in acute pulmonary sarcoidosis, which
becomes less prominent during the course of the disease
[15]. However, in a study using T cell clones from BALF,
Baumer et al. found equal levels of Th1 and Th2 cytokine
gene expression in patients with sarcoidosis [31]. Thus,
the purpose of the present study was to further investigate
the phenotype of T lymphocytes in BALF and in induced
sputum in patients with pulmonary sarcoidosis with focus
on expression of markers indicating Th1 and Th2 cellular
function. Our findings suggest a shift toward a type-1 phe-
notype in CD4+ T-cell populations in accordance with
previous studies in BALF and in peripheral blood [13-
15,32,33]. Intracellular cytokine staining could be useful
to study cytokine expression in sarcoidosis [6,14]. These
data are in agreement with those investigating the
cytokine profile of T cell subsets with other methods like
flow cytometry [13,32,33]. Inui et al. [13] investigated the
alteration of the Th1/Th2 and Tc1/ Tc2 balance in sar-
coidosis, using cytokine flow cytometry. The authors
showed for the first time a significantly higher percentage
of IFN-γ  producing CD4+ T cells together with a markedly
increased ratio of IFN-γ /IL-4-producing CD4+ T cells in
BALF, after PMA/ ionomycin stimulation in patients with
sarcoidosis compared with normal subjects. On the other
hand, there were no differences in the percentages of IFN-
γ  or IL-4- producing CD8+ T cells in either the peripheral
blood or BALF between patients and controls. In addition,
a recent report in eighteen patients with untreated sar-
coidoisis, examined the expression of Th1 associated
chemokine and cytokine receptors CXCR3, CCR5, and
interleukin IL-12R, IL-18R, respectively, as well as of the
Th2 associated chemokines receptors CCR4 and CXCR4
on CD4+ and CD8+ T cells [33]. That report showed the
lung accumulation of the above Th1 associated receptors,
in agreement with recent data of our group [34,35].
Conclusion
This report is the first to evaluate the critical balance of
Th1 to Th2 cells with the method of Induced sputum. In
conclusion, these data demonstrate that there are
increased numbers of CD4+ IFN-γ  producing T cells in
induced sputum from patients with pulmonary sarcoido-
sis, in accordance with the shift towards the Th1 response
known to exist in BALF and peripheral blood. The positive
correlation between the CD4+ IFN-γ  producing T cells in
BALF and in induced sputum, suggest that sarcoidosis
patients could be followed up with this noninvasive
method which has to be investigated in further studies.
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